Sangamo Therapeutics Inc (NASDAQ:SGMO) gapped up prior to trading on Thursday . The stock had previously closed at $15.55, but opened at $15.95. Sangamo Therapeutics shares last traded at $16.45, with a volume of 2029671 shares changing hands.

Several equities research analysts have issued reports on the stock. BidaskClub raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 17th. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 16th. ValuEngine downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 8th. Jefferies Group restated a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Finally, Wedbush restated a “hold” rating and issued a $8.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $21.67.

The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 0.14. The company has a market cap of $1.57 billion, a P/E ratio of -23.50 and a beta of 2.83.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.52). Sangamo Therapeutics had a negative net margin of 126.96% and a negative return on equity of 30.96%. The firm had revenue of $12.60 million during the quarter, compared to analyst estimates of $53.09 million. During the same quarter in the prior year, the firm posted ($0.23) EPS. The firm’s revenue for the quarter was up 270.6% on a year-over-year basis. equities research analysts forecast that Sangamo Therapeutics Inc will post -0.59 earnings per share for the current year.

In other news, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $24.78, for a total value of $123,900.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Curt A. Herberts III sold 2,278 shares of the company’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $18.30, for a total transaction of $41,687.40. The disclosure for this sale can be found here. Insiders sold a total of 47,656 shares of company stock worth $934,303 in the last 90 days. 1.20% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Allianz Asset Management GmbH lifted its position in Sangamo Therapeutics by 128.6% during the 1st quarter. Allianz Asset Management GmbH now owns 243,642 shares of the biopharmaceutical company’s stock worth $4,629,000 after buying an additional 137,050 shares in the last quarter. Principal Financial Group Inc. lifted its position in Sangamo Therapeutics by 7.7% during the 1st quarter. Principal Financial Group Inc. now owns 54,480 shares of the biopharmaceutical company’s stock worth $1,035,000 after buying an additional 3,910 shares in the last quarter. Nexthera Capital LP lifted its position in Sangamo Therapeutics by 11.0% during the 1st quarter. Nexthera Capital LP now owns 786,376 shares of the biopharmaceutical company’s stock worth $14,941,000 after buying an additional 77,832 shares in the last quarter. Hilltop Holdings Inc. acquired a new position in Sangamo Therapeutics during the 1st quarter worth about $406,000. Finally, Cubist Systematic Strategies LLC lifted its position in Sangamo Therapeutics by 193.6% during the 1st quarter. Cubist Systematic Strategies LLC now owns 65,087 shares of the biopharmaceutical company’s stock worth $1,237,000 after buying an additional 42,917 shares in the last quarter. Institutional investors and hedge funds own 56.37% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.